

DOCKET NO.: BIOL0002US (formerly 23546-08072)  
Application No.: 10/789,526  
Office Action Dated: October 3, 2005

PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A compound of from 8 to 80 12 to 50 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound comprises at least an 8-nucleobase portion of SEQ ID NO: 19 and specifically hybridizes with said nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4) or ~~SEQ ID NO: 18) and inhibits the expression of growth hormone receptor.~~
2. (Canceled)
3. (Original) A compound according to claim 1 which is from 15 to 30 nucleobases in length.
4. (Original) A compound according to claim 1 comprising an oligonucleotide.
5. (Original) A compound according to claim 4 in which the oligonucleotide is an antisense oligonucleotide.
6. (Original) A compound according to claim 4 in which the oligonucleotide is a DNA oligonucleotide.
7. (Original) A compound according to claim 4 in which the oligonucleotide is a RNA oligonucleotide.
8. (Original) A compound according to claim 4 in which the oligonucleotide is a chimeric oligonucleotide.
9. (Original) A compound according to claim 7 which is a short interfering RNA (siRNA) molecule.

DOCKET NO.: BIOL0002US (formerly 23546-08072)  
Application No.: 10/789,526  
Office Action Dated: October 3, 2005

PATENT

10. (Currently Amended) A compound according to claim 1 having comprising at least 70% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18)

11. (Currently Amended) A compound according to claim 1 having comprising at least 80% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18).

12. (Currently Amended) A compound according to claim 1 having comprising at least 90% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18).

13. (Currently Amended) A compound according to claim 1 having comprising at least 95% complementarity with the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4 or SEQ ID NO: 18).

14.-19. (Canceled)

20. (Currently Amended) A compound according to claim 1 comprising having at least one modified internucleoside linkage, sugar moiety, or nucleobase, or combination thereof.

21. (Currently Amended) A compound according to claim 20 having comprising at least one 2'-O-methoxyethyl sugar moiety.

22. (Currently Amended) A compound according to claim 20 having comprising at least one phosphorothioate internucleoside linkage.

23. (Currently Amended) A compound according to claim 20 having comprising at least one 5-methylcytosine.

DOCKET NO.: BIOL0002US (formerly 23546-08072)  
Application No.: 10/789,526  
Office Action Dated: October 3, 2005

PATENT

24.-45. (Canceled)

46. (New) An antisense oligonucleotide comprising a nucleobase sequence of SEQ ID NO: 19 and further comprising a ten deoxynucleotide region flanked on both the 5' and the 3' ends with five 2'-O-(2 methoxyethyl) nucleotides, wherein each internucleoside linkage is a phosphorothioate and each cytosine is a 5-methylcytosine.

47. (New) A pharmaceutical composition comprising the antisense oligonucleotide of claim 46 and a composition selected from the group consisting of a pharmaceutically acceptable carrier, diluent, penetration enhancer, excipient or combinations thereof.

48. (New) An antisense oligonucleotide that specifically hybridizes with a region of SEQ ID NO: 4, wherein the region comprises at least an 8-nucleobase portion of SEQ ID NO:161.

49. (New) An antisense oligonucleotide that specifically hybridizes with a region of SEQ ID NO: 4, wherein the region comprises SEQ ID NO:161.